ABSTRACT
INTRODUCTION
Adeno-associated viral (AAV) vectors are gene transfer vehicles derived from a replication-deficient member of the parvovirus family with a singlestranded 4.7-kb DNA genome. These vectors are attractive for in vivo gene transfer to a number of target cells including hepatocytes, muscle fibers, neurons, photoreceptors, and airway epithelial cells (1, 5, 21, 26) . AAV vectors do not contain viral coding sequences, can efficiently transduce non-dividing target cells, resulting in long-term transgene expression, and have an excellent toxicity and safety profile (2, 11, 20, 22) . Phase I clinical trials in patients with hemophilia B (HB) or with cystic fibrosis (CF) have been initiated using muscle or liver (HB) or airway epithelial cells (CF) as targets for transfer of an AAV vector encoding a coagulation factor IX (HB) or CFTR (CF) gene (3, 12, 18, 23) . Many of the preclinical studies for these trials have been carried out in large-animal models, namely hemophilic dogs and nonhuman primates (6, 11, 17, 20, 24) . Experiments in these animals may represent a greater than 2-log scale-up from murine models (10-20-kg dogs vs. a 25-g mouse), which illustrates the need for efficient scale-up of vector production even in a setting of preclinical experimentation (10) . AAV vectors can be produced by triple transfection of human embryonic kidney (HEK-293) cells without the need for a helper virus (7, 15, 27) . Advantages of this system include the fact that vectors with different expression cassettes or of different AAV serotypes can be rapidly produced simply by exchanging the vector plasmid or the AAV helper plasmid. In the latter case, we utilize plasmids that retain the AAV-2 rep gene but contain cap genes of the alternate serotype to be produced (19, 25) . The third plasmid includes adenovirus helper genes, thereby bypassing the need for a helper virus. However, scaleup of this technique has been labor intensive and cumbersome because of unsuccessful vector production in culture vessels that are larger than standard tissue culture plates or flasks. Here we demonstrate successful production of high-titer AAV vector in roller bottles, which represents a 10-fold scale-up from conventional methods.
MATERIALS AND METHODS

Plasmids
The three plasmids our laboratory currently uses for AAV vector production are a vector plasmid encoding an expression cassette for the transgene flanked by AAV-2 inverted terminal repeats, a second plasmid encoding AAV replication and capsid functions (p5E18 for production of AAV-2), and a third plasmid containing adenoviral helper genes E2A, E4, and VA (4). All AAV helper plasmids have been engineered to reduce rep gene expression (resulting in increased vector production) and to reduce the potential for generation of pseudo-wild-type AAV in vector preparations (4, 14, 16, 25) . 
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Plasmid Production
Scale-up of triple transfection requires large amounts of plasmid DNA, which we produce by using the GIGA plasmid DNA purification kit from Qiagen (Valencia, CA, USA) for vector and AAV helper plasmids. Since the adenoviral helper plasmid is identical for all vector production runs, we have been producing large stocks of this DNA using the Ultrapure-100 column from Qiagen loaded with lysate from 40 L E. coli (DH5α strain) culture, yielding 90 ± 38 mg plasmid DNA/ preparation (n = 4 preparations).
Vector Production
Viral vectors were produced by triple transfection in a helper virus-free system using HEK-293 cells (15) . The optimized transfection protocol is documented in the Results section. Tissue culture media DMEM (with high glucose and L-glutamine) and IMDM (containing NaHCO 3 and 25 mM HEP-ES) were obtained from Invitrogen (Carlsbad, CA, USA).
Vector Purification
Cells were harvested 84-96 h posttransfection, pelleted by a 30-min centrifugation step at 1000× g at 4°C, resuspended in a small volume of 10 mM Tris buffer, pH 8.0, and frozen at -80°C. Cells were lysed by ultra-sonication, and vector was purified by repeated CsCl density gradient centrifugation and filter-sterilized as described previously (8, 11) . Vector yields were determined by quantitative slot blot hybridization as described (8, 13) .
RESULTS AND DISCUSSION
Optimization of Transfection
The transfection step is most critical for achieving high-titer vector yield. In our optimized protocol, the three plasmids are mixed in an approximately equal molar ratio in 250 mM CaCl 2 solution (1 mg total plasmid DNA in 25 mL CaCl 2 solution, sufficient for transfection of 20 150-mm plates; CaCl 2 solution is prepared from filter-sterilized 1 M stock stored at -20°C). HEPES buffer (0.3 M NaCl, 40 mM HEPES, pH 7.05, autoclaved and stored at room temperature) is mixed with 70 mM Na 2 HPO 4 (autoclaved and stored at room temperature) at a ratio of 50:1. Preparing and storing separate phosphate and HEPES solutions increased transfection efficiency by 3-to 12-fold compared with preparing a buffer containing both components and yielded much improved stability of the pH during storage (both solutions can be stored for at least three months without a measurable loss of transfection efficiency; data not shown). HEPES/phosphate buffer (25 mL) is added to a 200-mL conical tube, which is placed on a vortex, and 25 mL DNA/CaCl 2 solution are added drop-wise while constantly vortex mixing. Subsequently, a DNA precipitate is allowed to form by incubation at room temperature for about 25 min. For scale-up, such batches of transfection cocktail are produced in approximately 5-min intervals for transfection of plates (or shorter intervals for roller bottle method; see below). The pH of the HEPES buffer is critical for efficient transfection. We tested buffer solutions differing by 0.05 pH units and obtained optimal results with pH 7.05 (9) . Transfection efficiency dropped by greater than 1 log for solutions with pH greater than 7.1. As pH meter instruments and standards may give slightly variable results, we suggest that each laboratory perform similar testing to determine an optimal pH value.
Vector Production in Plates
Using this optimized transfection procedure, AAV vectors were produced by transfection of HEK-293 cells grown to 80%-90% confluence in 150-mm plates. Before transfection, media (20 mL/plate) was changed from DMEM/-10% FBS/antibiotics to IMDM/2% FBS/antibiotics. The DNA precipitate was briefly vortex mixed and then added to conditioned media (2.5 mL containing 50 µg plasmid DNA/plate). Plates were returned to the incubator (37°C, 5% CO 2 in air), and media were changed to DMEM/2% FBS/antibiotics after 6-8 h. Cells were harvested 84-96 h post-transfection, processed as outlined in Materials and Methods, and vector purified by repeated CsCl gradient centrifugation as described previously (8) . Using these methods, we were able to routinely produce 10 11 -10 13 vector genomes (vg) per 10 plates (as determined by quantitative slot blot hybridization), depending on the construct and serotype (Table 1 AAV2 vector encoding a GFP reporter gene was generated in three different experiments (i.e., parallel preparations in 20 plates and two bottles). At the day of cell harvest (84-96 h post-transfection), cells were examined using fluorescence microscopy or were analyzed using FACS for GFP expression to determine transfection efficiency. These data were used to calculate the average number of vector particles (in vg) produced per transfected cell. 
Vector Production in Cell Factories
As manipulation of individual plates represents a time-consuming and laborintensive process, it is not suitable for scale-up of vector production. Therefore, we tested alternative tissue culture vessels with higher capacity for cell growth. Cell factories (Nalge Nunc International, Rochester, NY, USA) with a surface area of 6000 cm 2 (10-stack, approximately equivalent to 40.5 of 150-mm plates by area) were tested first. Cells were grown in cell factories until 80%-90% confluent (about 3 days of growth after inoculation with 1-2 × 10 8 cells) and then triple-transfected to generate an AAV2-GFP vector. An equivalent number of 150-mm plates were transfected in parallel. In two separate experiments, vector yield was 5-to 20-fold lower from the cell factory than with the plate method (data not shown).
Vector Production in Roller Bottles
Roller bottles (expanded surface roller bottles with easy-grip caps; Corning, Acton, MA, USA) with a surface area of 1700 cm 2 (approximately equivalent to 11.5 of 150-mm plates by area) were subsequently tested as a culture container. Cells were seeded at equivalent ratio in 150-mm plates or roller bottles (5 × 10 6 /plate and 5 × 10 7 /roller bottle). Using roller bottles, HEK-293 cells were grown in 200 mL DMEM/10% FBS/antibiotics. Media changes to IMDM or DMEM medium were performed as described above for plates, using 200 mL media/bottle. Roller bottles were incubated in a water-jacketed CO 2 (5% in air) incubator containing a cell culture roller apparatus with a maximum capacity of 35 bottles. A total of three parallel preparations of 20 plates or two roller bottles were done. When cells in 150-mm plates were 80%-90% confluent (2-3 days of growth), triple transfection was performed to generate an AAV2-GFP vector. Transfection cocktail was added to the media of each bottle at the amount of 25 mL calcium phosphate precipitate containing 0.5 mg plasmid DNA (i.e., the equivalent amount of DNA added to 10 plates). Cells were counted and examined at harvest day (day 4 post-transfection) for GFP expression by either fluorescence microscopy (one preparation) or by FACS ® (BD Biosciences, San Jose, CA, USA) (two preparations). The percentage of green-fluorescent cells was used to estimate the transfection efficiency. As shown in Table 1 , vector yield from roller bottles was on average 3-fold lower than from plates. This was in part due to somewhat reduced transfection efficiency in the bottles and in part due to a 2-fold greater yield of cells from plates, while the number of viral particles produced per transfected cell was similar for both methods (Table 1) . When 10-fold serial dilutions of AAV-GFP vector preparations were tested for transduction of HEK-293 cells in the presence of adenovirus, the ratio of total to infectious particles was 1:100-1:1000 for both production methods, as one would have expected for AAV vector purified by CsCl density centrifugation (data not shown).
Optimization of Vector Production in Roller Bottles
Cell counts suggested that cell growth in the roller bottles had reached only about 50% of the capacity of the bottles as determined by the available surface area. In subsequent experiments, we attempted to improve gas exchange between bottles and incubator by loosening bottle caps, which were secured with autoclave tape, an inexpensive alternative to the use of vented caps. Furthermore, we evaluated the influence of the amount of cell inoculum per bottle on vector yield and determined glucose levels in conditioned media at the time of transfection as an indicator for cell growth (Table 2 ). In this series of parallel transfections, AAV-GFP vector yield from roller bottles was identical to the yield from plates and similar for a wide range of cell inocula (Table 2 and Figure 1B) . Again, transfection was carried out once cells in plates were 80%-90% confluent. The data show that seeding of 5 × 10 7 cells/bottle (cells from one fully confluent 150-mm plate, representing a 1:10 cell split on the basis of surface area) is sufficient to achieve adequate cell growth for production of high-titer AAV vector. With this modification for improved gas exchange, cell numbers at the time of harvest/bottle were similar to cell yield from 10 plates (data not shown). Glucose consumption over time in media of roller bottles following inoculation with 8 × 10 7 cells was similar to consumption in 150-mm plates inoculated with 5 × 10 6 cells ( Figure 1A ), suggesting similar growth characteristics when adequate exchange of gases between the culture vessel and the incubator is established. This may not have been the case for the cell factory, which could explain the unsuccessful scale-up of vector production in that system. In follow-up experiments, we Increasing numbers of cells were used to inoculate cultures in roller bottles in parallel with inoculation of 10 150-mm plates (1:10 split). When cells in 150-mm plates reached 80%-90% confluence, glucose concentrations in conditioned media were determined. At this time point, cells were triple-transfected to produce an AAV2-GFP vector. Vector yields from each different preparation are shown (10 plates or one bottle/preparation). (Figure 2 ) allowed us to manufacture high-titer AAV vectors of different serotypes reproducibly (Table 3) . Pseudotyped AAV-5 vectors typically gave a somewhat higher yield, and AAV-1 vectors gave a 2-to 5-fold lower yield for the same vector genome compared with the AAV-2 vector. In summary, AAV vector can be produced at high titer by triple transfection of HEK-293 cells in roller bottles. Vector yields of 10 12 to greater than 10 13 vg/bottle have been routinely obtained with this method, which allows convenient scale-up in the laboratory with greatly reduced labor, time, and risk of contamination that is associated with handling large amounts of individual flasks or plates. Costs for plastic ware, media, and plasmid DNA are identical for roller bottle production and conventional tissue culture plate methods, thus making this method attractive for academic laboratories and core facilities. Yields are per 10 plates or per bottle as titered by quantitative slot blot hybridization. All vectors were purified by CsCl gradient centrifugation. Indicated are AAV serotype, promoter, and transgene as present in the expression cassette encoded by the vector.Yields are mean in vg ± SD for 3-5 preparations except for AAV2-CMV-F.IX produced in roller bottles (one preparation only). Factor IX is human factor IX. CMV, cytomegalovirus. 
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